Literature DB >> 24519701

Intraganglionic injection of a nitric oxide donator induces afferent mechanical sensitization that is attenuated by palmitoylethanolamide.

Brian E Cairns1, Jens C Laursen2, Xu-Dong Dong3, Parisa Gazerani4.   

Abstract

AIM: The aim of this article is to investigate whether the nitric oxide (NO) donator diethylenetriamine/nitric oxide (DETA/NO) affects trigeminal sensory processing through the trigeminal ganglion in part by activating trigeminal satellite glial cells (SGCs) and whether this effect is attenuated by the anti-inflammatory compound palmitoylethanolamide (PEA).
METHODS: DETA/NO was administered to isolated rat trigeminal SGCs in vitro, and injected into the rat trigeminal ganglion in vivo, in the presence or absence of PEA.
RESULTS: Administration of DETA/NO (1000 µM) increased the release of prostaglandin E2 by SGCs. PEA (1 and 10 µM) significantly attenuated prostaglandin E2 release. Two intraganglionic injections of DETA/NO (10 mM, 3 µl) or prostaglandin E2 at a 30-minute interval did not evoke discharge in trigeminal ganglion neurons that innervate the rat jaw-closer muscles, but did reduce the mechanical activation threshold of their peripheral endings by 30%-50%. Intravenous administration of PEA (1 mg/kg) or ketorolac (0.5 mg/kg) prevented DETA/NO-induced afferent mechanical sensitization.
CONCLUSIONS: Elevation of NO in the trigeminal ganglion results in the sensitization of the peripheral endings of masticatory muscle nociceptors to mechanical stimulation through a mechanism that involves prostaglandin E2 release from SGCs. Attenuation of this sensitization by PEA suggests a possible option for acute management of craniofacial pain and headache. © International Headache Society 2014 Reprints and permissions: sagepub.co.uk/journalsPermissions.nav.

Entities:  

Keywords:  Headache; glial modulators; nitric oxide; palmitoylethanolamide; satellite glial cells; trigeminal ganglion

Year:  2014        PMID: 24519701     DOI: 10.1177/0333102414521510

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  6 in total

1.  Micronized palmitoylethanolamide reduces joint pain and glial cell activation.

Authors:  Maria Lavinia Bartolucci; Ida Marini; Francesco Bortolotti; Daniela Impellizzeri; Rosanna Di Paola; Giuseppe Bruschetta; Rosalia Crupi; Marco Portelli; Angela Militi; Giacomo Oteri; Emanuela Esposito; Salvatore Cuzzocrea
Journal:  Inflamm Res       Date:  2018-08-18       Impact factor: 4.575

2.  Elevated Fractalkine (CX3CL1) Levels in the Trigeminal Ganglion Mechanically Sensitize Temporalis Muscle Nociceptors.

Authors:  Brian E Cairns; Melissa O'Brien; Xu-Dong Dong; Parisa Gazerani
Journal:  Mol Neurobiol       Date:  2016-05-21       Impact factor: 5.590

Review 3.  ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.

Authors:  Ramona D'Amico; Daniela Impellizzeri; Salvatore Cuzzocrea; Rosanna Di Paola
Journal:  Int J Mol Sci       Date:  2020-07-27       Impact factor: 5.923

Review 4.  Satellite Glial Cells in Pain Research: A Targeted Viewpoint of Potential and Future Directions.

Authors:  Parisa Gazerani
Journal:  Front Pain Res (Lausanne)       Date:  2021-03-10

Review 5.  Palmitoylethanolamide, a Natural Retinoprotectant: Its Putative Relevance for the Treatment of Glaucoma and Diabetic Retinopathy.

Authors:  Jan M Keppel Hesselink; Ciro Costagliola; Josiane Fakhry; David J Kopsky
Journal:  J Ophthalmol       Date:  2015-11-18       Impact factor: 1.909

Review 6.  Molecular mechanisms underlying the actions of arachidonic acid-derived prostaglandins on peripheral nociception.

Authors:  Yongwoo Jang; Minseok Kim; Sun Wook Hwang
Journal:  J Neuroinflammation       Date:  2020-01-22       Impact factor: 8.322

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.